Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


European HTA Network Rejects Industry Criticism Of Joint Clinical Assessments

Executive Summary

EUnetHTA 21, the EU health technology assessment network that will soon hang up its hat has defended the methodologies it developed to support the EU HTA Regulation in the wake of criticism from industry.

You may also be interested in...

EMA Waves Goodbye To HTA Network As Collaboration Framework Enters New Phase

A report published by the European Medicines Agency highlights milestones reached under its collaboration with EUnetHTA over recent years and outlines areas for further development once the initiative changes hands under the new HTA Regulation.

EU HTA Regulation: What Comes After The Joint Clinical Assessments?

More clarity is needed on how member states plan to adapt their health technology appraisal procedures once the requirement kicks in for them to factor in EU-level joint clinical assessments.

Proposed Methodologies For EU Joint Clinical Assessment Are Threat To ATMPs and Rare Disease Patients

Sixteen out of 18 EU-approved advanced therapy medicinal products would fail to pass an EU-wide joint clinical assessment because proposed methodologies are unsuitable for such products, according to the Alliance for Regenerative Medicine.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts